Allergan's Botox Gets FDA OK for More Muscles in Adult Spasticity
July 29 2021 - 9:12AM
Dow Jones News
By Colin Kellaher
AbbVie Inc.'s Allergan unit Thursday said the U.S. Food and Drug
Administration approved the expanded use of Botox to include eight
new muscles for the treatment of upper limb spasticity in
adults.
Allergan said the approval covers additional muscles of the
elbow and forearm, along with intrinsic hand muscles and thumb
muscles.
The company said Botox's label now also includes the use of
ultrasound as a muscle localization technique in adult spasticity,
which is commonly caused by stroke, multiple sclerosis, spinal-cord
injury, cerebral palsy and traumatic brain injury.
Botox, which the FDA first approved in 1989 for a pair of rare
eye muscle disorders, is currently FDA-approved for a dozen
therapeutic indications.
AbbVie, a North Chicago, Ill., biopharmaceutical company,
completed its roughly $63 billion acquisition of Allergan last
year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 29, 2021 09:03 ET (13:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024